---
aliases: [EXAS]
---
#actor #genomics #diagnostics #cancer #usa #public

**Exact Sciences** — Cancer screening leader. Cologuard (20M+ tests). Cancerguard multi-cancer. ~$3.1B revenue.

---

## Why Exact Sciences matters

| Metric | Value |
|--------|-------|
| Ticker | EXAS |
| Market cap | ~$12B |
| 2025E revenue | **$3.13-3.17B** |
| HQ | Madison, WI |
| Cologuard tests | **20M+ lifetime** |

---

## 2025 financial performance

| Quarter | Revenue | YoY growth |
|---------|---------|------------|
| Q1 2025 | $707M | +11% |
| Q2 2025 | $811M | +16% |
| Q3 2025 | $851M | +20% |

---

## Business segments

| Segment | Q3 2025 revenue | Growth |
|---------|-----------------|--------|
| **Screening** | $666M | +22% |
| Precision Oncology | $183M | +12% |

---

## Product portfolio

### Screening

| Product | Application | Status |
|---------|-------------|--------|
| **Cologuard Plus** | CRC screening | Launched Q1 2025 |
| Cologuard | CRC screening (original) | 20M+ tests |
| **Cancerguard** | Multi-cancer (50+ types) | Launched Sep 2025 |

### Precision Oncology

| Product | Application |
|---------|-------------|
| Oncotype DX Breast | Breast cancer recurrence |
| Oncotype DX Colon | Colon cancer recurrence |
| OncoExTra | Comprehensive tumor profiling |

---

## Cologuard Plus (2025 launch)

| Improvement | Detail |
|-------------|--------|
| Cancer sensitivity | Higher than original |
| Precancer detection | Improved |
| False positives | **-40%** reduction |
| Provider adoption | 200K+ orders in Q2 |

**Milestone:** Cologuard approaching colonoscopy volume parity.

---

## Cancerguard (Sep 2025 launch)

| Feature | Detail |
|---------|--------|
| Cancer types | **50+** |
| Method | Blood-based (liquid biopsy) |
| Competition | Grail Galleri, Guardant |
| [[Target]] | Average-risk screening |

---

## Competitive landscape

| Competitor | Product | Approach |
|------------|---------|----------|
| **Exact Sciences** | Cologuard, Cancerguard | Stool + blood |
| [[Guardant Health]] | Shield | Blood-based CRC |
| Grail ([[Illumina]]) | Galleri | Multi-cancer blood |
| [[Natera]] | Signatera | MRD (not screening) |
| Freenome | Blood CRC | Development |

---

## Market opportunity

| Metric | Value |
|--------|-------|
| CRC screening eligible (US) | ~50M |
| Current screening rate | ~60% |
| Cologuard penetration | Growing |
| Multi-cancer TAM | Massive (45+ population) |

---

## Investment case

**Bull:**
- Cologuard Plus driving reacceleration
- Cancerguard multi-cancer opportunity
- 200K+ provider relationships
- "Transformative year" (2025)
- Market leader in non-invasive CRC

**Bear:**
- Shield (Guardant) competition in blood CRC
- Multi-cancer market crowded
- Reimbursement uncertainty for Cancerguard
- Margin pressure from launches
- Colonoscopy still gold standard

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | EXAS |
| 2025E revenue | ~$3.15B |
| Key product | Cologuard |
| Focus | Cancer screening |

---

## Related

- [[Guardant Health]] — competitor (Shield)
- [[Natera]] — competitor (MRD)
- [[Illumina]] — Grail competitor
- [[Genomics]] — sector concept
- [[Biopharma]] — sector

---

## Sources

- [Exact Sciences Q3 2025](https://www.investing.com/news/company-news/exact-sciences-q3-2025-slides-20-revenue-growth-guidance-raised-93CH-4328951)
- [Cologuard Plus Launch](https://www.exactsciences.com/newsroom/press-releases/exact-sciences-announces-second-quarter-2025-results)

*Created 2026-01-09*
